DelveInsight is a prominent provider of valuable research within biotech and pharmaceutical industries. It offers analytical reports in such Health Care sectors as gene therapy, medical oncologic therapy, Active Pharmaceutical Ingredient (API) manufacturing, stem cell medication, biosimilars, orphan drugs and others. The expertise includes:
- Company’s profile and licensing data;
- New technology studies;
- Biologic benchmarking;
- Treatment modality analysis;
- Competitive landscape;
- Product assessment; etc.
This knowledge is essential for Generic and Drug Development companies, which also receive drug sales estimation and product performance forecasts.
DelveInsight reconciles customers need for information and for innovative approaches in business development. Consequently, the obtained data is turned into strategic design, partner up opportunities, profit earning capacity of the business. DelveInsight analysts assist pharma enterprises in launching new products and marketing development of existing pharmaceutics.
Publications found:
6,889
Sort by:
HER+ Gastric Cancer - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'HER+ Gastric Cancer - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, hi...
January 2022
60 pages
HER2+ Gastric Cancer—Epidemiology Forecast—2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'HER2+ Gastric Cancer - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, h...
January 2022
60 pages
HER2 Lung Cancer - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'HER2 Lung Cancer - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, histo...
January 2022
60 pages
HER2-Negative Breast Cancer - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'HER2-Negative Breast Cancer - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the dis...
January 2022
60 pages
HER2-Positive Breast Cancer - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'HER2-Positive Breast Cancer - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the dis...
January 2022
60 pages
Herpes Genitalis - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Herpes Genitalis - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, histo...
January 2022
60 pages
Herpes Keratitis - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Herpes Keratitis - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, histo...
January 2022
60 pages
Herpes Zoster Oticus - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Herpes Zoster Oticus - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, h...
January 2022
60 pages
Hidradenitis - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Hidradenitis - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historica...
January 2022
60 pages
High Grade Glioma - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'High Grade Glioma - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, hist...
January 2022
60 pages
Histamine H1 receptor antagonists - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 48 hours DelveInsight’s, “Histamine H1 Receptor Antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies an...
January 2022
60 pages
HIV integrase inhibitors - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 24 Hours DelveInsight’s, “HIV integrase inhibitors - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipe...
January 2022
60 pages
Hodgkin Lmphoma - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Hodgkin Lmphoma - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, histor...
January 2022
60 pages
Homocystinuria - Epidemiology Insight - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Homocystinuria - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, histori...
January 2022
60 pages
House Dust Mite Allergy - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'House Dust Mite Allergy - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease...
January 2022
60 pages
HR-Positive-HER-negative - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'HR-Positive-HER-negative - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the diseas...
January 2022
60 pages
Hunter Syndrome - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Hunter Syndrome - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, histor...
January 2022
60 pages
Hydrocephalus - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Hydrocephalus - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historic...
January 2022
60 pages
